Skip to main content
logo
Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
11.94
+0.11 (0.93%)
At close: Apr 8, 2026, 4:00 PM EDT
12.14
+0.20 (1.68%)
After-hours: Apr 8, 2026, 6:31 PM EDT

Generate Biomedicines Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024
Period Ending
Dec '25 Dec '24
Cash & Equivalents
121.65176.27
Short-Term Investments
99.85217.36
Cash & Short-Term Investments
221.5393.63
Cash Growth
-43.73%-
Receivables
-0.31
Prepaid Expenses
12.5312.13
Restricted Cash
0.341.43
Total Current Assets
234.37407.49
Property, Plant & Equipment
89.01101.07
Other Long-Term Assets
6.819.7
Total Assets
330.18518.26
Accounts Payable
3.845.67
Accrued Expenses
39.5419.34
Current Portion of Leases
15.0116.72
Current Unearned Revenue
21.1942.43
Other Current Liabilities
2.632.48
Total Current Liabilities
82.286.63
Long-Term Leases
53.5260.26
Long-Term Unearned Revenue
4.5115.17
Other Long-Term Liabilities
0.120.35
Total Liabilities
140.35162.4
Common Stock
0.050.05
Additional Paid-In Capital
60.1738.45
Retained Earnings
-676.29-473.14
Comprehensive Income & Other
0.110.12
Total Common Equity
-615.97-434.52
Minority Interest
-7.23-0.57
Shareholders' Equity
189.83355.86
Total Liabilities & Equity
330.18518.26
Total Debt
68.5376.97
Net Cash (Debt)
152.97316.66
Net Cash Growth
-51.69%-
Net Cash Per Share
3.056.50
Filing Date Shares Outstanding
50.349.66
Total Common Shares Outstanding
50.349.66
Working Capital
152.16320.87
Book Value Per Share
-12.24-8.75
Tangible Book Value
-615.97-434.52
Tangible Book Value Per Share
-12.24-8.75
Machinery
42.9219.61
Construction In Progress
4.110.89
Leasehold Improvements
9.669.63
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q